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Abstract: Oral contraceptives are classically given in a cyclic manner with 21 days of active 
pills followed by 7 days of placebo. In the past 4 years, new oral contraceptives have been 
introduced which either shorten the placebo time, lengthen the active pills (extended cycle), or 
provide active pills every day (continuous). These concepts are not new; extended and continuous 
pills were ﬁ  rst studied in the 1960s and 1970s and have been provided in an off-label manner 
by gynecologists to treat menstrual disorders, such as menorrhagia and dysmenorrhea, and 
gynecologic disorders, such as endometriosis. Now that extended and continuous combined oral 
contraceptives are available for all patients, it is critical for providers to understand the physiol-
ogy, dosing, side effects, and beneﬁ  ts of this form of oral contraceptive. This article reviews the 
history and the potential uses of the new continuous combined oral contraceptive.
Keywords: oral contraceptives, administration, dosage, adverse effects, menstrual disturbances
Introduction
Oral hormonal contraceptives (OCPs) were developed over 40 years ago as an effec-
tive, immediately reversible contraceptive. During this time, the doses of estrogen and 
progestin decreased, thus lessening the potential risk while maintaining efﬁ  cacy. More 
recently the contraceptives have been altered to shorten or eliminate placebo pills to 
lessen menstrual symptoms. Combination hormonal contraceptives are typically taken 
orally, but transdermal and vaginal administration are also available.
The presence of cyclic bleeding is not essential for the contraceptive action of 
OCPs and studies indicate that many women are interested in reducing the frequency of 
their menstruation (den Tonkelaar and Oddens 1999; Edelman et al 2006; Trego 2007; 
Wiegratz et al 2004). Despite early research indicating that extended cycles were safe, 
until recently the pill was marketed exclusively in the 21 day active + 7 day placebo 
cycle format (Loudon et al 1977; Miller and Hughes 2003; Anderson and Hait 2003). 
Randomized trials have now proven the safety and efﬁ  cacy of extended (24 active + 4 
placebo, 84 active + 7 placebo) and continuous hormonal dosing (Coutinho et al 1995; 
Miller and Notter 2001; Archer et al 2006). This article will review the pharmacology 
of oral contraceptives and focus on studies evaluating the safety, efﬁ  cacy, and patient 
satisfaction of continuous OCPs.
Pharmacology
Estradiol is the major estrogen produced by the ovary but its use is limited due to poor 
absorption when taken in a non-micronized form. The addition of an ethinyl group 
to the 17 position renders the species orally active and thus ethinyl estradiol is the 
most common estrogen available in modern OCPs. Mestranol, another orally active 
estrogen available in OCPs, is converted to ethinyl estradiol in the body. The original 
dose of ethinyl estradiol was higher than current medication; most modern OCPs Therapeutics and Clinical Risk Management 2008:4(5) 906
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contain 20–35 μg of ethinyl estradiol and offer comparable 
safety and efﬁ  cacy and reduced incidence of adverse events 
(Speroff and DeCherney 1993).
Pharmacologic progestins were created by removing the 
19 carbon from ethisterone, a derivative of testosterone. The 
19-nortestosterone progestins used in OCPs are of two major 
types, called estranes and gonanes. Gonanes have greater 
progestational activity per unit weight than do estranes, 
requiring a lower dosing of gonanes for effectiveness in 
OCP formulations. Estranes correspond to ﬁ  rst-generation 
progestins and include norethisterone, norethindrone, 
ethynodiol diacetate, lynestrenol, and norethynodrel. Gonane 
progestins are divided into two categories: the second-
generation progestins levonorgestrel and norgestrel, and 
the third-generation progestins desogestrel, gestodene, and 
norgestimate. New progestins are being examined for con-
traceptive use including drospirenone, derived from spirono-
lactone, an antimineralocorticoid medication; dienogest, a 
norethindrone-like structure that acts as an antiandrogen; and 
three 19-norprogesterone derivatives nestorone, nomegestrol 
acetate, and trimegestone (Sitruk-Ware 2006). The overall 
difference between progestin families in modern OCP 
formulations is minimal. OCPs are formulated to contain 
the lowest effective dose, and similar biologic effects are 
seen with various progestins; no studies have demonstrated 
that one progestin provides superior efﬁ  cacy (Speroff and 
DeCherney 1993).
Side effect proﬁ  les related to OCPs vary somewhat 
based on type of the type of progestin. Less patient initiated 
discontinuation and improved cycle control with less inter-
menstrual bleeding has been reported with second- compared 
with ﬁ  rst-generation progestins. Patient acceptability of 
third- and second-generation progestins is greater than that 
of ﬁ  rst-generation preparations (Maitra et al 2008).
The primary contraceptive mechanism of the combina-
tion OCP is to prevent ovulation by inhibiting gonadotropin 
secretion at both the level of the pituitary gland and the hypo-
thalamus. The estrogen component of OCPs directly inhibits 
follicle-stimulating hormone (FSH) secretion and thus limits 
the development of the dominant ovulatory follicle. The 
progestin component of the OCP profoundly suppresses 
luteinizing hormone (LH) secretion and thus reliably prevents 
the LH surge which triggers ovulation (Mishell et al 1977).
In a normally menstruating woman who is not taking 
contraceptive hormones, progesterone is only present 
in appreciable quantities during the luteal phase of the 
menstrual cycle, after the development of the endometrium. 
When combination OCPs are administered, the effect of 
the progestational agent takes precedence over the estrogen 
component in the reproductive tract, and the endometrium 
demonstrates this progestin effect (Moyer and Felix 1998). 
The result is a thin, decidualized endometrium with atro-
phied glands that is not receptive to embryo implantation. 
Progestins also cause thick, impermeable cervical mucus, 
preventing sperm from reaching the uterine cavity, and 
decreases tubal mobility, altering the movement of sperm 
and oocytes through the fallopian tube (Johnson et al 2007; 
Rossmanith et al 1997).
Although progestin alone is an effective contraceptive, 
there are beneﬁ  ts when estrogen and progestin are combined 
in an OCP. By directly inhibiting FSH, estrogen contributes 
to the contraceptive efﬁ  cacy of the OCP by limiting follicu-
lar development. In the endometrium, estrogen stimulation 
provides stability and may decrease irregular breakthrough 
bleeding seen with progestin only contraceptives (Mahmood 
et al 1998). Estrogen also potentiates the action of progesta-
tional agents, presumably by increasing the concentration of 
intracellular progestin receptors (Kastner et al 1990). This 
latter effect may decrease the progesterone dose required in 
the combination OCP.
OCP cycle formulations
The original OCP was designed to allow monthly bleeding. It 
was presumed that regular withdrawal bleeding was critical 
to increase acceptance of the OCPs. However, this bleeding 
is not a physiologic menstrual period. Physiologic menses 
occur due to estradiol-induced endometrial growth, followed 
by progesterone-induced decidualization of the endome-
trium, and bleeding with the withdrawal of progesterone and 
estradiol. With OCPs, the only portion of the cycle with unop-
posed estrogen occurs during the placebo week, when FSH is 
not suppressed and the ovary produces estradiol. The active 
pills provide a progestin and thus prevent future growth of 
the endometrium. By limiting or eliminating the placebo pills, 
the endometrium will not develop and withdrawal bleeding 
will not occur. With continuous hormonal contraceptives 
there is limited development of the endometrium. Although 
bleeding may occur with extended or continuous OCPs, due 
to atrophic changes in the endometrium, there is no typical 
endometrium to shed.
The concept of extended and continuous hormonal 
contraceptives is not new. The ﬁ  rst investigation of an 
extended combination OCP regimen was performed in 
the 1970s (Loudon et al 1977). This non-randomized trial 
evaluated the effect of an extended cycle regimen of 84 
days of a combination OCP containing lynoestrenol 2.5 mg Therapeutics and Clinical Risk Management 2008:4(5) 907
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and ethinyl estradiol 50 μg on 196 women. No pregnancies 
occurred during the 1-year study period and 82% of women 
who completed the study reported that they welcomed the 
reduction in menstruation. Twenty-four percent of women 
reported breakthrough vaginal spotting during the ﬁ  rst 3 
months of the trial but this rate decreased to 4% during the 
last 3 months of use. The ﬁ  rst randomized study evaluating 
an extended cycle regimen was conducted in 1993 (Cachri-
manidou et al 1993). This multicenter study compared the 
acceptance of desogestrel 150 μg and ethinyl estradiol 
30 μg dosed in a cyclic or extended regimen. There was 
signiﬁ  cantly more breakthrough bleeding in the extended 
cycle group, but this decreased throughout the year and was 
signiﬁ  cantly less in women who were using an OCP prior 
to enrolling in the trial. Signiﬁ  cantly more women stopped 
the trial because of   bleeding problems in the extended 
cycle group, while signiﬁ  cantly more women stopped the 
trial because of headache in the standard cycle group. No 
signiﬁ  cant differences were found in body weight changes, 
hemoglobin, or blood pressure between the two groups. 
After trials to conﬁ  rm efﬁ  cacy and safety, extended cycle oral 
contraceptives became available in 2003 (Miller and Hughes 
2003; Anderson and Hait 2003).
The first randomized trial of combined continuous 
OCPs was published in 1995 (Coutinho et al 1995). This 
multicenter, international trial evaluated the acceptability, 
efﬁ  cacy, and safety of levonorgestrel 250 μg and ethinyl 
estradiol 50 μg administered vaginally either cyclically or 
continuously. Nine hundred subjects were randomized to 
traditional cyclic administration or continuous administration 
for one year. Interestingly, four undesired pregnancies 
occurred in the cyclic administration group and none occurred 
in the continuous administration group; this difference was 
statistically signiﬁ  cant (p = 0.0486).
Two continuous OCP trials were published in 2003 (Miller 
and Notter 2001; Kwiecien et al 2003). Miller et al evaluated 
79 women randomized to receive cyclic or continuous oral 
levonorgestrel 100 μg and ethinyl estradiol 20 μg for 336 days 
(Miller and Notter 2001). No pregnancies were reported. 
Amenorrhea or infrequent bleeding was present in 68% of 
continuous users during the ﬁ  rst three cycles and this increased 
to 88% during the last three cycles of the trial. There was no 
difference in adverse events, and blood pressure, weight and 
hemoglobin ﬁ  ndings were not signiﬁ  cantly different between 
groups. Kwiecien et al published a randomized trial assessing 
bleeding patterns and acceptability of cyclic versus continuous 
OCP dosing of oral levonorgestrel 100 μg and ethinyl estradiol 
20 μg (Kwiecien et al 2003). Thirty-two women were randomized 
and 28 participants (87%) completed the 168 day trial. No preg-
nancies occurred during the study period however one occurred 
in the continuous OCP group after completion of the study. The 
number of bleeding days based on menstrual diaries was less in 
the continuous group but did not reach statistical signiﬁ  cance. 
The continuous group had signiﬁ  cantly higher rates of amenor-
rhea and signiﬁ  cantly decreased menstrual pain and bloating.
A single-treatment, multicenter, open-label Phase 3 trial 
evaluating the safety and efﬁ  cacy of continuous dosing of 
levonorgestrel 90 μg and ethinyl estradiol 20 μg in 2134 
women led to FDA approval of a continuous combined 
OCP in 2007 (Archer et al 2006). Fifteen pregnancies were 
attributed to method failure, giving a Pearl Index of 1.26. The 
most common side effect of amenorrhea was expected with 
continuous OCP; at pill pack 13 58.7% reported amenor-
rhea and 79.0% reported absence of bleeding. Subjects with 
bleeding decreased from 93.9% at pill pack 1 to 21.0% at pill 
pack 13; 860 subjects completed all 13 pill packs.
Efﬁ  cacy
The most common question asked by patients is the effec-
tiveness of the contraceptive in preventing pregnancy. With 
perfect use, cyclic oral contraceptives are highly effective; 
0.3% of women have an unwanted pregnancy when taken 
perfectly for 1 year. Unfortunately, with typical use the rate 
rises to 8% of women in 1 year of OCP use (Trussell 2004). 
The most common risk with OCPs is imperfect use, typically 
due to “missed pills.” When pills are missed at start of the 
pack and the days without active pills are extended, the risk 
of ovulation may increase (Tayob et al 1990). Continuous 
OCPs would potentially lessen this risk by reducing the 
number of active pills missed when the start of the pill pack 
is delayed.
Efficacy studies of extended and continuous cycle 
OCPs demonstrate that these regimens are as effective as 
cyclic administration. The largest study to date evaluating 
an extended cycle regimen in 456 patients demonstrated a 
pregnancy rate of 0.9% compared with a 1.3% pregnancy 
rate in the standard cycle group over the course of 1 year 
(Anderson and Hait 2003). Two smaller randomized one year 
long studies of extended regimens reported no pregnancies in 
99 and 198 patients (Coutinho et al 1995; Miller and Notter 
2001). The largest study of continuous OCP users evaluated 
2134 women, 19 of whom became pregnant during the 1-year 
study period. Fifteen of these pregnancies were attributed to 
method failure (Archer et al 2006). Another large study ran-
domized 900 women to cyclic or continuous use for one year 
(Coutinho et al 1995). Four undesired pregnancies occurred Therapeutics and Clinical Risk Management 2008:4(5) 908
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in the cyclic administration group and none occurred in the 
continuous administration group; this difference was statisti-
cally signiﬁ  cant (p = 0.05). Two smaller studies randomizing 
cyclic and continuous use OCPs demonstrated no pregnancies 
in either group during the study period (Miller and Hughes 
2003; Kwiecien et al 2003).
Limitations/side effects
The most commonly reported side effect with continuous 
or extended regimen OCP dosing is breakthrough vaginal 
bleeding. Studies evaluating this side effect have reported 
its presence to varying degrees. In a large trial of continuous 
oral contraceptives, 396 patients (18.5%) withdrew due to 
bothersome uterine bleeding, making this the most common 
reason to withdraw from the study (Archer et al 2006). 
A Cochrane review evaluated 6 randomized controlled trials 
with extended or continuous OCPs (Edelman et al 2005). 
Although the differences between the medications and 
duration of the studies limited comparison between trials, 
the authors concluded that bleeding patterns were either 
equivalent or improved with the extended or continuous 
dosing regimen. The extended or continuous cycle groups 
also fared better with respect to headaches, genital irritation, 
tiredness, bloating, and menstrual pain in the studies that 
evaluated these side effects. There were no overall differ-
ences observed in contraceptive efﬁ  cacy, safety proﬁ  les, 
compliance, discontinuation rates or patient satisfaction 
between cyclic and continuous users.
Amenorrhea rates for the 3 largest studies are sum-
marized in Table 1. Collectively these data indicate that 
most patients on continuous OCPs will obtain amenor-
rhea after 1 year of treatment but the exact incidence is 
difficult to quantify given the slightly different hormonal 
regimens used by each study. Additionally, the incidence 
of breakthrough bleeding and spotting is initially high 
with continuous dosing but appears to decrease consis-
tently over time. Whether amenorrhea rates would con-
tinue to increase after one year of treatment is uncertain 
because no studies have evaluated treatment beyond 
one year. The total number of bleeding days is less with 
continuous dosing than with traditional cyclic dosing 
although the timing of bleeding with continuous dosing 
will not typically occur at predictable intervals. Finally, 
the incidence of vaginal spotting was either increased or 
unchanged with continuous dosing in studies comparing 
continuous to traditional cyclic dosing (Miller and Notter 
2001; Kwiecien et al 2003; Archer et al 2006).
Although breakthrough bleeding is a temporary problem 
for some women on continuous OCPs, providers can reassure 
women that this bleeding does not demonstrate an endome-
trial abnormality. Studies evaluating endometrial histology 
on continuously dosed OCPs have found reassuring results. 
A substudy of a large Phase 3 trial evaluated baseline and 
on therapy endometrial histology of 93 subjects taking 
continuous levonorgestrel 90 μg and ethinyl estradiol 20 μg 
(Johnson et al 2007). Endometrial biopsies were performed 
at baseline and after at least 6 months of treatment. Before 
treatment, 60% of subjects had a endometrial histology clas-
siﬁ  ed as proliferative; after 6 months of continuous OCP, 
most subjects (52%) had endometrial histology classiﬁ  ed 
as other, indicating benign and inactive endometrium. Only 
3 subjects had proliferative endometrim with continuous 
OCP use. No endometrial hyperplasia or malignancy was 
found in any biopsy specimen. Another substudy evalu-
ated endometrial thickness on transvaginal ultrasound and 
endometrial biopsies of 11 women on continuous levonorg-
estrel 90 μg and ethinyl estradiol 20 μg and 7 women on a 
traditional 28 day cycle of the same hormonal combination 
(Miller and Notter 2001). All subjects had endometrial stripe 
measurements <5 mm and 88% of continuous use subjects 
had inactive or atrophic endometrial biopsies. In contrast, 
60% of cyclic use subjects had proliferative endometrium 
on biopsy. No endometrial hyperplasia or malignancy was 
identiﬁ  ed.
The resumption of menses after discontinuation of 
continuous OCPs has been shown to occur within 60 days for 
94.7% of subjects; 75% had menses in 36 days or less (Davis 
et al 2008). In addition, in a small study, 81% of women 
achieved pregnancy within a year of discontinuation of the 
OCP (Barnhart et al 2006). This supports the theory that con-
tinuous OCPs, as with cyclic dosing, provides an effective and 
immediately-reversible contraceptive option for women.
Side effects with continuous combined OCPs were not 
increased when compared to cyclic OCPs (Coutinho et al 
1995; Miller and Notter 2001; Kwiecien et al 2003). As 
expected with oral contraceptives, a modest number of 
subjects reported adverse effects with continuous OCPs 
in the Phase 3 trial such as abdominal pain (9.6%), back 
Table 1 Amenorrhea rates in users of continuous oral 
contraceptives containing levonorgesterel in 3 large studies (each 
pill pack contained a 28-day supply)
Pill packs 1–3 Pill pack 12–13
Coutinho (1995) 67.6% 87.5%
Miller (2003) 16% 72%
Archer (2006) 2.3% 58.7%Therapeutics and Clinical Risk Management 2008:4(5) 909
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pain (10%), and headache (30%), although these effects 
were not compared to placebo or cyclic OCPs. Bothersome 
uterine bleeding caused 18.5% of subjects to withdraw from 
the study. Rare serious adverse events included two subjects 
with cholecystitis, one thrombotic event, one ectopic preg-
nancy, one prolonged uterine bleeding, and one enlarged 
uterine ﬁ  broids (Archer et al 2006).
OCPs have several known metabolic effects including 
increased production of clotting factors resulting in increased 
risk of venous thromboembolism, increased gallstone forma-
tion during the ﬁ  rst year of use, and increased risk of liver 
adenomas (Speroff and DeCherney 1993). Limited informa-
tion is available on the metabolic effects of continuous or 
extended OCPs. One small study randomized 30 women to 
a cyclic versus extended regimen and found no differences 
in liver proteins, lipoproteins, and hemostatic variables at 
0, 3, and 12 months (Cachrimanidou et al 1994). The small 
increased temporal exposure to synthetic hormones, associ-
ated with extended or continuous OCP use, is unlikely to 
result in signiﬁ  cant metabolic differences compared with 
traditional cyclic administration.
Noncontraceptive beneﬁ  ts
Clearly, extended and continuous oral contraceptives are 
effective in lessening menstrual bleeding, but these medica-
tions may also lessen other menstrual symptoms. It is reported 
that 20%–40% of women have signiﬁ  cant menstrual-related 
symptoms, adversely effecting over 2.5 million women in 
the US (Kjerulff et al 1996). Table 2 summarizes menstrual 
conditions that may be improved with extended or continu-
ous cycle OCPs. Several studies have evaluated the utility 
of extended and continuously dosed OCPs for reducing 
menstrual symptoms including dysmenorrhea and pre-
menstrual symptoms. One study demonstrated that of  267 
patients who initiated an extended regimen for menstrual 
symptoms, 64% preferred the extended regimen while 21% 
discontinued OCPs and 14% returned to a standard OCP 
regimen (Sulak et al 2002). Another study of 50 patients 
with menstrual-related problems including dysmenorrhea, 
menorrhagia, premenstrual-type symptoms, and menstrual 
migraines found that 74% stabilized on an extended regimen 
cycle OCP regimen while 26% either discontinued OCPs or 
returned to the standard regimen (Sulak et al 1997).
In addition to lessening menstrual symptoms, continuous 
oral contraceptives may be effective at reducing symptoms 
related to other gynecologic conditions such as ovarian cysts, 
pelvic pain, and endometriosis. Continuous OCPs effectively 
suppress ovarian activity and ovulation as evidenced by one 
study in which 91.7% of women on continuous OCPs had no 
active follicles seen on transvaginal ultrasound (Archer et al 
2005). An Italian study evaluated continuously dosed OCPs 
as a treatment for dysmenorrhea associated with endometrio-
sis (Vercellini et al 2003). This study evaluated women with 
surgically treated endometriosis who had persistent dysmen-
orrhea on cyclic OCPs. A signiﬁ  cant reduction in the mean 
dysmenorrhea visual analog scale was noted with continuous 
OCP therapy and of the 50 women who completed the trial, 
26% reported being very satisﬁ  ed and 54% reported being 
satisﬁ  ed with this treatment.
Patient perspectives
Studies indicate that regularly cycling women are inter-
ested in reducing the frequency of menstruation. A Dutch 
telephone survey evaluating attitudes towards menstrua-
tion in reproductive aged women demonstrated that 80.5% 
preferred less painful menses, shorter menses, less heavy 
menses and/or amenorrhea to their current cycle. Most 
of the menstruating women in all age groups preferred 
to have a bleeding frequency of less than once a month 
or never, and this result was more signiﬁ  cant in older 
women and in women using OCPs (den Tonkelaar and 
Oddens 1999). A similar German survey of 1195 women 
aged 18–49 found that 26%–35% of the women preferred 
monthly bleeding, while 37%–46% wished never to bleed. 
Women who preferred fewer menses reported a desire for 
fewer severe menstrual complaints, better hygiene, higher 
quality of life, and less blood loss. Women who preferred 
monthly bleeding cited concerns such as fear of pregnancy, 
infertility and adverse events and a belief that menstruation 
is natural (Wiegratz et al 2004). Finally, a survey conducted 
in the US indicated that 69% of women did not like their 
menstrual period and 58% preferred a menstrual frequency 
of every 3 months or never. However, only 29% of black 
women would consider a birth control method to stop their 
menstrual periods compared with 49% of white women 
(Edelman et al 2007).
Table 2 Conditions that may be improved with continuous and 
extended cycle oral contraceptives
Dysmenorrhea (Archer 2005;   Vercellini 2003)
Menstrual migraine (Archer 2005;   Vercellini 2003)
Premenstrual syndrome (Archer 2005;   Vercellini 2003)
Menorrhagia (Archer 2005;   Vercellini 2003)
Ovarian cysts (Edelman 2007)
Endometriosis (Schneider 1999)
Pelvic pain (Schneider 1999)Therapeutics and Clinical Risk Management 2008:4(5) 910
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For some careers, the cessation of menses is advantageous 
for women. Any job which limits hygiene, such as active-duty 
military, may be simpliﬁ  ed by reducing menses. More than 
60% of active-duty military women state that menstrual symp-
toms adversely affect their work (Schneider et al 1999).
Despite relatively high patient drop-out rates in some stud-
ies evaluating extended regimen and continuous OCPs, high 
patient satisfaction has been consistently reported. In one of 
the original studies evaluating extended regimen OCPs, 91% 
of women who completed the trial refused to revert back to a 
standard monthly dosing regimen due to their satisfaction with 
the extended cycle regimen (Loudon et al 1977). Another study 
evaluating an extended regimen showed that most patients rated 
their overall satisfaction with the extended cycle OCP regimen 
as good to excellent and stated they would choose to have fewer 
menstrual periods after the completion of the study (Anderson 
and Hait 2003). For continuous use OCPs, patient satisfaction 
is as high as with cyclic users; 78.1% of women planned to 
continue using continuous OCP dosing at completion of the 
study and 18.8% planning to switch to cyclic use (Kwiecien 
et al 2003). Similarly, 67.9% of cyclic users planned to continue 
cyclic use and 21.4% planned to try continuous use.
Concern about possible pregnancy appears to be low in 
patients taking continuous OCPs, with 4 out of  79 patients citing 
“a little” concern in one study (Kwiecien et al 2003). Clinical 
experience and study surveys indicate that some women prefer 
to have monthly withdrawal bleeding to provide reassurance 
that they are not pregnant. Appropriate counseling on the con-
traceptive efﬁ  cacy of continuously dosed OCPs would likely 
reassure many of these patients. Pregnancy tests can certainly be 
offered to patients on continuous OCPs; however, many other 
contraceptive methods cause menstrual irregularity or suppres-
sion and routine pregnancy tests are not medically indicated for 
these patients. Importantly, OCPs are not teratogenic and do not 
increase the risk of fetal malformations.
Finally, a survey evaluating physician attitudes towards 
extended or continuous OCP dosing in adolescents reveals 
that 90% of surveyed physicians reported ever prescribing 
extended or continuous dosing regimens (Gerschultz et al 
2007). Gynecologists were more likely than other special-
ties to prescribe frequent extended cycles or continuous 
regimens and 33% reported that extended cycles make up 
greater than 10% of their total OCP prescriptions. The most 
common reasons for prescribing extended or continuous 
regimens were to accommodate patients’ requests to induce 
amenorrhea for specific events (82%), to obtain fewer 
menses per year (72%), and to treat menorrhagia (68%), 
dysmenorrhea (65%), or endometriosis (62%).
Conclusions
Continuous OCPs are a safe and reliable form of birth 
control. The metabolic, hormonal, and endometrial effects 
are similar in cyclic and continuous OCP users. The most 
commonly reported side effect of continuous OCP dosing 
is irregular vaginal bleeding, but the incidence of this 
decreases over time and most patients will obtain amenor-
rhea after 1 year of treatment. Continuous OCP dosing has 
proven efﬁ  cacious in women with menstrual symptoms 
and dysmenorrhea, although larger randomized studies 
are indicated. Patient satisfaction with both cyclic and 
continuous OCP use is high. Candidates for continuous 
OCP dosing include anyone who is a candidate for tradi-
tional cyclic OCPs dosing; no additional contraindications 
exist. Additionally, there is no temporal limitation to the 
use of continuous OCPs as excellent safety data exist for 
endometrial histology. Women who wish to limit cyclic 
bleeding, for personal or medical reasons, are excellent 
candidates for continuous OCPs. It is appropriate for 
practitioners to offer both dosing regimens for any patient 
interested in starting an OCP and continuous dosing may 
be preferable for patients with dysmenorrhea or other 
menstrual symptoms.
Guidelines
•  Extended and continuous cycle OCPs have equal efﬁ  cacy 
to classic 21 + 7 cyclic OCPs.
•  Although bleeding patterns, compared with classic cyclic 
OCPs, have been shown to be equivalent or improved 
with extended or continuous cycle OCPs, bothersome 
uterine bleeding is the most common reason for with-
drawal from studies. Patients can be advised of this 
potential side effect.
•  There is no increased concern of endometrial abnormali-
ties with extended or continuous OCPs.
•  Extended or continuous OCPs decrease menstrual 
symptoms, including dysmenorrhea and premenstrual 
symptoms.
•  Women who desire fewer menses, for occupational or 
personal reasons, may be considered for extended or 
continuous OCPs.
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